Drug intelligence / Profile preview

bifidobacterium longum BL21

Development stage: Unknown
Lead developer: Wecare Probiotics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Topical

Overview

Bifidobacterium longum BL21 is a specific probiotic strain of the species Bifidobacterium longum, isolated from the intestines of healthy infants. [7] Developed by Wecare Probiotics, it is being investigated for various health benefits. [6, 9, 10] Clinical studies are evaluating its potential therapeutic effects. A Phase II trial has assessed its use in preventing acute radiation-induced intestinal injury (enteritis) in patients undergoing pelvic radiotherapy. [1, 2, 5] Another clinical trial is examining its impact on glucose metabolism in patients with type 2 diabetes. [4] Preclinical and clinical research suggests that its mechanism of action involves modulating the gut microbiota, which can influence the digestive, immune, and metabolic systems. [1, 15] Further research has explored its potential in areas such as colorectal cancer, constipation, liver health, weight management, and polycystic ovary syndrome (PCOS). [3, 6, 15]

Brand names: WecLac Bifidobacterium Longum BL21
Other names: Bifidobacterium longum subsp. longum BL21

Beyond the preview

Go deeper on bifidobacterium longum BL21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium longum BL21.

Explore the full profile